التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
Sanofi SA
Open
Sector Healthcare
92.16 1.74
Overview
Share price change
24h
Min
90.42
Max
92.16
Income | 1.7B 2.8B |
|---|---|
Sales | 2.1B 13B |
P/E Sector Avg | 30.62 94.998 |
EPS | 2.86 |
Dividend yield | 3.944 |
Profit margin | 20.945 |
EBITDA | 2.2B 4.2B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +23.62 upside |
Dividend yield Sector Avg | 3.94% 2.40% |
|---|---|
Next Earnings | ٣٠ يناير ٢٠٢٥ |
Market Cap | 113B |
|---|---|
Previous open | 90.42 |
Previous close | 92.16 |
News Sentiment
By Acuity
34%
66%
100 / 392 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Neutral Evidence
Sanofi SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Sanofi SA Forecast
Price Target
By TipRanks
23.62% upside
12 Months Forecast
Average 112.334 EUR 23.62%
High 130 EUR
Low 90 EUR
Based on 13 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.
Sentiment
By Acuity
100 / 392 Ranking in Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Sanofi SA
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
